RU2018145009A - Производное бензилфенилового эфира, способ его получения и его фармацевтическая композиция и применение - Google Patents
Производное бензилфенилового эфира, способ его получения и его фармацевтическая композиция и применение Download PDFInfo
- Publication number
- RU2018145009A RU2018145009A RU2018145009A RU2018145009A RU2018145009A RU 2018145009 A RU2018145009 A RU 2018145009A RU 2018145009 A RU2018145009 A RU 2018145009A RU 2018145009 A RU2018145009 A RU 2018145009A RU 2018145009 A RU2018145009 A RU 2018145009A
- Authority
- RU
- Russia
- Prior art keywords
- substituted
- bromo
- amino
- alkylamino
- hydrogen
- Prior art date
Links
- BOTNYLSAWDQNEX-UHFFFAOYSA-N phenoxymethylbenzene Chemical class C=1C=CC=CC=1COC1=CC=CC=C1 BOTNYLSAWDQNEX-UHFFFAOYSA-N 0.000 title claims 16
- 238000004519 manufacturing process Methods 0.000 title claims 3
- 238000000034 method Methods 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- -1 cyano, methylsulfonyl Chemical group 0.000 claims 81
- 239000001257 hydrogen Substances 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 21
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 13
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 13
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 13
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 13
- 229910052794 bromium Inorganic materials 0.000 claims 13
- 239000000460 chlorine Substances 0.000 claims 13
- 229910052801 chlorine Inorganic materials 0.000 claims 13
- 229910052731 fluorine Inorganic materials 0.000 claims 13
- 239000011737 fluorine Substances 0.000 claims 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 9
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 9
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 125000003282 alkyl amino group Chemical group 0.000 claims 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 8
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 8
- 125000002883 imidazolyl group Chemical group 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 125000002971 oxazolyl group Chemical group 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 8
- 125000003831 tetrazolyl group Chemical group 0.000 claims 8
- 125000000335 thiazolyl group Chemical group 0.000 claims 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 208000018359 Systemic autoimmune disease Diseases 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 150000001299 aldehydes Chemical class 0.000 claims 2
- 229910001413 alkali metal ion Inorganic materials 0.000 claims 2
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 150000007522 mineralic acids Chemical class 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 150000007530 organic bases Chemical class 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 239000007858 starting material Substances 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 2
- YWABMIPZXRUWMO-HXUWFJFHSA-N (2R)-2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-5-chloro-2-[(3-cyanophenyl)methoxy]phenyl]methylamino]propanoic acid Chemical compound C[C@@H](NCc1cc(Cl)c(OCc2cccc(c2Br)-c2ccccc2)cc1OCc1cccc(c1)C#N)C(O)=O YWABMIPZXRUWMO-HXUWFJFHSA-N 0.000 claims 1
- QSFMQVZPFLLGAE-HHHXNRCGSA-N (2R)-2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-5-chloro-2-[(3-methylsulfonylphenyl)methoxy]phenyl]methylamino]-3-hydroxypropanoic acid Chemical compound CS(=O)(=O)c1cccc(COc2cc(OCc3cccc(c3Br)-c3ccccc3)c(Cl)cc2CN[C@H](CO)C(O)=O)c1 QSFMQVZPFLLGAE-HHHXNRCGSA-N 0.000 claims 1
- JJUHERGUJPOSRG-PMERELPUSA-N (2S)-1-[[4-[(2-bromo-3-phenylphenyl)methoxy]-2-[(3-cyanophenyl)methoxy]phenyl]methyl]pyrrolidine-2-carboxylic acid Chemical compound C(#N)C=1C=C(COC2=C(CN3[C@@H](CCC3)C(=O)O)C=CC(=C2)OCC2=C(C(=CC=C2)C2=CC=CC=C2)Br)C=CC=1 JJUHERGUJPOSRG-PMERELPUSA-N 0.000 claims 1
- DYDQRLKTIGIFNQ-NDEPHWFRSA-N (2S)-2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-2-[(3-cyanophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanoic acid Chemical compound C(#N)C=1C=C(COC2=C(CN[C@@H](CO)C(=O)O)C=CC(=C2)OCC2=C(C(=CC=C2)C2=CC=CC=C2)Br)C=CC=1 DYDQRLKTIGIFNQ-NDEPHWFRSA-N 0.000 claims 1
- APZFUDKGLHAODF-PMERELPUSA-N (2S)-2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-2-[(3-cyanophenyl)methoxy]phenyl]methylamino]-4-methylsulfanylbutanoic acid Chemical compound C(#N)C=1C=C(COC2=C(CN[C@@H](CCSC)C(=O)O)C=CC(=C2)OCC2=C(C(=CC=C2)C2=CC=CC=C2)Br)C=CC=1 APZFUDKGLHAODF-PMERELPUSA-N 0.000 claims 1
- GSJUKYYDHBOJEP-MHZLTWQESA-N (2S)-2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-5-chloro-2-[(3-cyanophenyl)methoxy]phenyl]methylamino]-3-hydroxypropanoic acid Chemical compound C(#N)C=1C=C(COC2=C(CN[C@@H](CO)C(=O)O)C=C(C(=C2)OCC2=C(C(=CC=C2)C2=CC=CC=C2)Br)Cl)C=CC=1 GSJUKYYDHBOJEP-MHZLTWQESA-N 0.000 claims 1
- XFKXOSGLTSBDOU-UHFFFAOYSA-N 3-[[5-[(2-bromo-3-phenylphenyl)methoxy]-2-(morpholin-4-ylmethyl)phenoxy]methyl]benzonitrile hydrochloride Chemical compound Cl.Brc1c(COc2ccc(CN3CCOCC3)c(OCc3cccc(c3)C#N)c2)cccc1-c1ccccc1 XFKXOSGLTSBDOU-UHFFFAOYSA-N 0.000 claims 1
- BNDZSSLNLGLVNW-UHFFFAOYSA-N 3-[[5-[(2-bromo-3-phenylphenyl)methoxy]-2-[(2-hydroxyethylamino)methyl]phenoxy]methyl]benzonitrile Chemical compound OCCNCC1=C(C=C(C=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)Br)OCC1=CC(=CC=C1)C#N BNDZSSLNLGLVNW-UHFFFAOYSA-N 0.000 claims 1
- WXJWMMOWQMYFEV-UHFFFAOYSA-N 3-[[5-[(2-bromo-3-phenylphenyl)methoxy]-2-[(oxan-4-ylamino)methyl]phenoxy]methyl]benzonitrile Chemical compound Brc1c(COc2ccc(CNC3CCOCC3)c(OCc3cccc(c3)C#N)c2)cccc1-c1ccccc1 WXJWMMOWQMYFEV-UHFFFAOYSA-N 0.000 claims 1
- NAIUVKUYNPIQQV-UHFFFAOYSA-N 3-[[5-[(2-bromo-3-phenylphenyl)methoxy]-2-[[ethyl(2-hydroxyethyl)amino]methyl]phenoxy]methyl]benzonitrile Chemical compound C(C)N(CCO)CC1=C(C=C(C=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)Br)OCC1=CC(=CC=C1)C#N NAIUVKUYNPIQQV-UHFFFAOYSA-N 0.000 claims 1
- WFKSDDBJJFYOET-UHFFFAOYSA-N 3-[[5-[(2-bromo-3-phenylphenyl)methoxy]-4-chloro-2-[(2-hydroxyethylamino)methyl]phenoxy]methyl]benzonitrile Chemical compound OCCNCc1cc(Cl)c(OCc2cccc(c2Br)-c2ccccc2)cc1OCc1cccc(c1)C#N WFKSDDBJJFYOET-UHFFFAOYSA-N 0.000 claims 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- IQLRLTODFXQGEP-UHFFFAOYSA-N N-[2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-2-[(3-cyanophenyl)methoxy]phenyl]methylamino]ethyl]acetamide Chemical compound C(C)(=O)NCCNCC1=C(C=C(C=C1)OCC1=C(C(=CC=C1)C1=CC=CC=C1)Br)OCC1=CC(=CC=C1)C#N IQLRLTODFXQGEP-UHFFFAOYSA-N 0.000 claims 1
- ILGOOJSWDMNSAR-UHFFFAOYSA-N N-[2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-2-[(3-cyanophenyl)methoxy]phenyl]methylamino]ethyl]methanesulfonamide hydrochloride Chemical compound Cl.CS(=O)(=O)NCCNCc1ccc(OCc2cccc(c2Br)-c2ccccc2)cc1OCc1cccc(c1)C#N ILGOOJSWDMNSAR-UHFFFAOYSA-N 0.000 claims 1
- OULXBALIHGTTTF-UHFFFAOYSA-N N-[2-[[4-[(2-bromo-3-phenylphenyl)methoxy]-5-chloro-2-[(3-cyanophenyl)methoxy]phenyl]methylamino]ethyl]acetamide Chemical compound CC(=O)NCCNCc1cc(Cl)c(OCc2cccc(c2Br)-c2ccccc2)cc1OCc1cccc(c1)C#N OULXBALIHGTTTF-UHFFFAOYSA-N 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 150000003935 benzaldehydes Chemical class 0.000 claims 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910001424 calcium ion Inorganic materials 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 229910001416 lithium ion Inorganic materials 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229910001425 magnesium ion Inorganic materials 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 206010061311 nervous system neoplasm Diseases 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910001414 potassium ion Inorganic materials 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000028466 reproductive system neoplasm Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 229910001415 sodium ion Inorganic materials 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
- C07C17/10—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
- C07C17/14—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms in the side-chain of aromatic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
- C07C17/263—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/12—Formation of amino and carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/18—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyrrole Compounds (AREA)
Claims (102)
1. Производное бензилфенилового эфира формулы (I):
или его стереоизомер или фармацевтически приемлемая соль,
где:
R2 выбран из водорода, циано, метилсульфонила, ацетиламино, карбамоила, диметиламиноформила (-CON(CH3)2), фтора, хлора, брома, йода, трифторметила, C1-C5 алкила и C1-C5 алкокси;
R3 выбран из замещенного C1-C8 насыщенного алкиламино, замещенного C2-C6 ненасыщенного алкиламино, замещенного N-содержащего C2-C6 гетероцикл-1-ила, где каждый моно-, ди-, три- или тетра-замещен заместителем(заместителями), выбранным из водорода, фтора, хлора, брома, йода, гидрокси, C1-C5 алкила, C1-C5 алкокси, амино, C1-C6 алкиламино, ацетиламино, циано, уреидо (-NH(C=O)NH2), гуанидино (-NH(C=NH)NH2), уреидо амино (-NH-NH(C=O)NH2), гуанидино амино (-NH-NH(C=NH)NH2), сульфониламино (-NHSO3H), сульфамоила (-SO2NH2), метансульфониламино (-NH-SO2CH3), гидроксиформила (-COOH), C1-C8 алкоксилкарбонила, сульфидрила, имидазолила, тиазолила, оксазолила, тетразолила, , и ;
X выбран из водорода, фтора, хлора, брома, йода, C1-C4 алкила, этенила, трифторметила, метокси.
2. Производное бензилфенилового эфира по п.1, представленное формулой (IA), или его фармацевтически приемлемая соль или стереоизомер
где:
R2 выбран из водорода, циано, метилсульфонила, ацетиламино, карбамоила, диметиламиноформила (-CON(CH3)2), фтора, хлора, брома, йода, трифторметила, C1-C5 алкила и C1-C5 алкокси;
R3 выбран из замещенного C1-C8 насыщенного алкиламино, замещенного C2-C6 ненасыщенного алкиламино, замещенного N-содержащего C2-C6 гетероцикл-1-ила, где каждый моно-, ди-, три- или тетра-замещен заместителем(ями), выбранным из водорода, фтора, хлора, брома, йода, гидрокси, C1-C5 алкила, C1-C5 алкокси, амино, C1-C6 алкиламино, ацетиламино, циано, уреидо (-NH(C=O)NH2), гуанидино (-NH(C=NH)NH2), уреидо амино (-NH-NH(C=O)NH2), гуанидино амино (-NH-NH(C=NH)NH2), сульфониламино (-NHSO3H), сульфамоила (-SO2NH2), метансульфониламино (-NH-SO2CH3), гидроксиформила (-COOH), C1-C8 алкоксилкарбонила, сульфидрила, имидазолила, тиазолила, оксазолила, тетразолила, , и ;
X выбран из водорода, фтора, хлора, брома, йода, C1-C4 алкила, этенила, трифторметила и метокси.
3. Производное бензилфенилового эфира по п.2, представленное формулой (IA-1), или его фармацевтически приемлемая соль или стереоизомер
где:
R2 выбран из водорода, циано, метилсульфонила, ацетиламино, карбамоила, диметиламиноформила (-CON(CH3)2), фтора, хлора, брома, йода, трифторметила, C1-C5 алкила и C1-C5 алкокси;
R3 выбран из замещенного C1-C8 насыщенного алкиламино, замещенного C2-C6 ненасыщенного алкиламино, замещенного N-содержащего C2-C6 гетероцикл-1-ила, где каждый моно-, ди-, три- или тетра-замещен заместителем(ями), выбранным из водорода, фтора, хлора, брома, йода, гидрокси, C1-C5 алкила, C1-C5 алкокси, амино, C1-C6 алкиламино, ацетиламино, циано, уреидо (-NH(C=O)NH2), гуанидино (-NH(C=NH)NH2), уреидо амино (-NH-NH(C=O)NH2), гуанидино амино (-NH-NH(C=NH)NH2), сульфониламино (-NHSO3H), сульфамоила (-SO2NH2), метансульфониламино (-NH-SO2CH3), гидроксиформила (-COOH), C1-C8 алкоксилкарбонила, сульфидрила, имидазолила, тиазолила, оксазолила, тетразолила, , и ;
X выбран из водорода, фтора, хлора, брома, йода, C1-C4 алкила, этенила, трифторметила и метокси.
4. Производное бензилфенилового эфира по п.3, представленное формулой (IA-1a), или его фармацевтически приемлема соль или стереоизомер:
где:
R3 выбран из замещенного C1-C8 насыщенного алкиламино, замещенного C2-C6 ненасыщенного алкиламино, замещенного N-содержащего C2-C6 гетероцикл-1-ила, где каждый моно-, ди-, три- или тетра-замещен заместителем(ями), выбранным из водорода, фтора, хлора, брома, йода, гидрокси, C1-C5 алкила, C1-C5 алкокси, амино, C1-C6 алкиламино, ацетиламино, циано, уреидо (-NH(C=O)NH2), гуанидино (-NH(C=NH)NH2), уреидо амино (-NH-NH(C=O)NH2), гуанидино амино (-NH-NH(C=NH)NH2), сульфониламино (-NHSO3H), сульфамоила (-SO2NH2), метансульфониламино (-NH-SO2CH3), гидроксиформила (-COOH), C1-C8 алкоксилкарбонила, сульфидрила, имидазолила, тиазолила, оксазолила, тетразолила, , и ;
X выбран из водорода, фтора, хлора, брома, йода, C1-C4 алкила, этенила, трифторметила и метокси.
5. Производное бензилфенилового эфира по п.3, представленное формулой (IA-1b), или его фармацевтически приемлема соль или стереоизомер:
где:
R3 выбран из замещенного C1-C8 насыщенного алкиламино, замещенного C2-C6 ненасыщенного алкиламино, замещенного N-содержащего C2-C6 гетероцикл-1-ила, где каждый моно-, ди-, три- или тетра-замещен заместителем(ями), выбранным из водорода, фтора, хлора, брома, йода, гидрокси, C1-C5 алкила, C1-C5 алкокси, амино, C1-C6 алкиламино, ацетиламино, циано, уреидо (-NH(C=O)NH2), гуанидино (-NH(C=NH)NH2), уреидо амино (-NH-NH(C=O)NH2), гуанидино амино (-NH-NH(C=NH)NH2), сульфониламино (-NHSO3H), сульфамоила (-SO2NH2), метансульфониламино (-NH-SO2CH3), гидроксиформила (-COOH), C1-C8 алкоксилкарбонила, сульфидрила, имидазолила, тиазолила, оксазолила, тетразолила, , и ;
X выбран из водорода, фтора, хлора, брома, йода, C1-C4 алкила, этенила, трифторметила и метокси.
6. Производное бензилфенилового эфира по п.2, представленное формулой (IA-2), или его фармацевтически приемлема соль или стереоизомер:
где:
R2 выбран из водорода, циано, метилсульфонила, ацетиламино, карбамоила, диметиламиноформила (-CON(CH3)2), фтора, хлора, брома, йода, трифторметила, C1-C5 алкила и C1-C5 алкокси;
R3 выбран из замещенного C1-C8 насыщенного алкиламино, замещенного C2-C6 ненасыщенного алкиламино, замещенного N-содержащего C2-C6 гетероцикл-1-ила, где каждый моно-, ди-, три- или тетра-замещен заместителем(ями), выбранным из водорода, фтора, хлора, брома, йода, гидрокси, C1-C5 алкила, C1-C5 алкокси, амино, C1-C6 алкиламино, ацетиламино, циано, уреидо (-NH(C=O)NH2), гуанидино (-NH(C=NH)NH2), уреидо амино (-NH-NH(C=O)NH2), гуанидино амино (-NH-NH(C=NH)NH2), сульфониламино (-NHSO3H), сульфамоила (-SO2NH2), метансульфониламино (-NH-SO2CH3), гидроксиформила (-COOH), C1-C8 алкоксилкарбонила, сульфидрила, имидазолила, тиазолила, оксазолила, тетразолила, , и ;
X выбран из водорода, фтора, хлора, брома, йода, C1-C4 алкила, этенила, трифторметила и метокси.
7. Производное бензилфенилового эфира по п.6, представленное формулой (IA-2a), или его фармацевтически приемлема соль или стереоизомер:
где:
R3 выбран из замещенного C1-C8 насыщенного алкиламино, замещенного C2-C6 ненасыщенного алкиламино, замещенного N-содержащего C2-C6 гетероцикл-1-ила, где каждый моно-, ди-, три- или тетра-замещен заместителем(ями), выбранным из водорода, фтора, хлора, брома, йода, гидрокси, C1-C5 алкила, C1-C5 алкокси, амино, C1-C6 алкиламино, ацетиламино, циано, уреидо (-NH(C=O)NH2), гуанидино (-NH(C=NH)NH2), уреидо амино (-NH-NH(C=O)NH2), гуанидино амино (-NH-NH(C=NH)NH2), сульфониламино (-NHSO3H), сульфамоила (-SO2NH2), метансульфониламино (-NH-SO2CH3), гидроксиформила (-COOH), C1-C8 алкоксилкарбонила, сульфидрила, имидазолила, тиазолила, оксазолила, тетразолила, , и ;
X выбран из водорода, фтора, хлора, брома, йода, C1-C4 алкила, этенила, трифторметила и метокси.
8. Производное бензилфенилового эфира по п.6, представленное формулой (IA-2b), или его фармацевтически приемлема соль или стереоизомер:
где:
R3 выбран из замещенного C1-C8 насыщенного алкиламино, замещенного C2-C6 ненасыщенного алкиламино, замещенного N-содержащего C2-C6 гетероцикл-1-ила, где каждый моно-, ди-, три- или тетра-замещен заместителем(ями), выбранным из водорода, фтора, хлора, брома, йода, гидрокси, C1-C5 алкила, C1-C5 алкокси, амино, C1-C6 алкиламино, ацетиламино, циано, уреидо (-NH(C=O)NH2), гуанидино (-NH(C=NH)NH2), уреидо амино (-NH-NH(C=O)NH2), гуанидино амино (-NH-NH(C=NH)NH2), сульфониламино (-NHSO3H), сульфамоила (-SO2NH2), метансульфониламино (-NH-SO2CH3), гидроксиформила (-COOH), C1-C8 алкоксилкарбонила, сульфидрила, имидазолила, тиазолила, оксазолила, тетразолила, , и ;
X выбран из водорода, фтора, хлора, брома, йода, C1-C4 алкила, этенила, трифторметила и метокси.
9. Производное бензилфенилового эфира по любому из пп.1-8, или его фармацевтически приемлема соль или стереоизомер, где R3 выбран из:
где R выбран из метила, этила, пропила, изопропила, бутила, пентила, гексила, гептила, октила;
X выбран из водорода, фтора, хлора, брома, метила, этенила и трифторметила.
10. Производное бензилфенилового эфира по п.1, или его фармацевтически приемлема соль или стереоизомер, где соединение выбрано из:
N-ацетиламиноэтил-4-(2-бром-3-фенилбензилокси)-2-(3-цианобензилокси)бензиламина
N-(4-(2-бром-3-фенилбензилокси)-2-(3-цианобензилокси)бензил)серина
N-Этил-N-гидроксилэтил-4-(2-бром-3-фенилбензилокси)-2-(3-цианобензилокси)бензиламина
N-(4-(2-бром-3-фенилбензилокси)-2-(3-цианобензилокси)бензил)пролина
N-гидроксилэтил-4-(2-бром-3-фенилбензилокси)-2-(3-цианобензилокси)бензиламина
N-(4-(2-бром-3-фенилбензилокси)-2-(3-цианобензилокси)бензил)аланина
N-(4-(2-бром-3-фенилбензилокси)-2-(3-цианобензилокси)бензил)метионина
N-(4-(2-бром-3-фенилбензилокси)-2-(3-цианобензилокси)бензил)треонина
N-(тетрагидро-2H-пиран-4-ил)-4-(2-бром-3-фенилбензилокси)-2-(3-цианобензилокси)бензиламина
N-[4-(2-бром-3-фенилбензилокси)-2-(3-цианобензилокси)бензил]морфолин гидрохлорида
N-(4-(2-бром-3-фенилбензилокси)-5-хлор-2-(3-цианобензилокси)бензил)серина
N-гидроксилэтил-4-(2-бром-3-фенилбензилокси)-5-хлор-2-(3-цианобензилокси)бензиламина
N-ацетиламиноэтил-4-(2-бром-3-фенилбензилокси)-5-хлор-2-(3-цианобензилокси)бензиламина
N-(2-метансульфониламиноэтил)-4-(2-бром-3-фенилбензилокси)-2-(3-цианобензилокси)бензиламин гидрохлорида
(S)-N-(4-(2-бром-3-(2,3-дигидробензо[b][1,4]диоксин-6-ил)бензилокси)-5-хлор-2-(3-цианобензилокси)бензил)пипеколиновой кислоты
N-(4-(2-бром-3-фенилбензилокси)-5-хлор-2-(3-цианобензилокси)бензил)аланина
N-(4-(2-бром-3-фенилбензилокси)-5-хлор-2-(3-цианобензилокси)бензил)треонина
N-(4-(2-бром-3-фенилбензилокси)-5-хлор-2-(3-метансульфонилбензилокси)бензил)серина
N-(4-(2-бром-3-фенилбензилокси)-5-хлор-2-(3-метансульфонилбензилокси)бензил)пипеколиновой кислоты
11. Производное бензилфенилового эфира по п.1, или его стереоизомер или фармацевтически приемлемая соль, где фармацевтически приемлемая соль включает соль, образованную с неорганической кислотой, соль, образованную с органической кислотой, соль с ионом щелочного металла, соль с ионом щелочноземельного металла или соль, образованную с органическим основанием, которое обеспечивает физиологически приемлемый катион, и соль аммония.
12. Производное бензилфенилового эфира по п.11, или его стереоизомер или фармацевтически приемлемая соль, где неорганическая кислота выбрана из хлористоводородной кислоты, бромистоводородной кислоты, фосфорной кислоты или серной кислоты; органическая кислота выбрана из метансульфоновой кислоты, п-толуолсульфоновой кислоты, трифторуксусной кислоты, лимонной кислоты, малеиновой кислоты, винной кислоты, фумаровой кислоты, лимонной кислоты или молочной кислоты; ион щелочного металла выбран из иона лития, иона натрия, иона калия; ион щелочноземельного металла выбран из иона кальция и иона магния; и органическое основание, которое обеспечивает физиологически приемлемый катион, выбрано из метиламина, диметиламина, триметиламина, пиперидина, морфолина или трис(2-гидроксиэтил)амина.
13. Способ получения производного бензилфенилового эфира по любому из пп.1-12, и его стереоизомера, и его фармацевтически приемлемой соли:
для получения соединений формулы (I), в соответствии с его структурой, способ получения разделяют на две стадии:
2-гидрокси-4-(2-бром-3-R1 бензилокси)-X-замещенный бензальдегид 1 в качестве исходного вещества подвергают взаимодействию с бензилгалогенидом, который является R2-замещенным в положении 3, в основных условиях с получением альдегидсодержащего промежуточного соединения 2;
альдегидсодержащее промежуточное соединение 2 в качестве исходного материала конденсируют с HR3, содержащей аминогруппу или иминогруппу, и полученный продукт восстанавливают с получением целевого соединения I;
где R1, R2, R3 и X, каждый, имеет значение, как определено в любом из пп. 1-12.
14. Фармацевтическая композиция, содержащая производное бензилфенилового эфира по любому из пп.1-12, или его стереоизомер или фармацевтически приемлемую соль, в качестве активного ингредиента, и один или несколько фармацевтически приемлемых носителей или эксципиентов.
15. Применение производного бензилфенилового эфира по любому из пп.1-12 или его стереоизомера или его фармацевтически приемлемой соли для получения лекарственного средства для профилактики и/или лечения заболевания, связанного с сигнальным путем PD-1/PD-L1.
16. Применение по п.15, где заболевание, связанное с сигнальным путем PD-1/PD-L1, выбрано из рака, инфекционного заболевания и аутоиммунного заболевания.
17. Применение по п.16, где рак выбран из рака кожи, рака легких, опухоли мочеполовой системы, опухоли крови, рака молочной железы, глиомы, опухоли пищеварительной системы, опухоли репродуктивной системы, лимфомы, опухоли нервной системы, опухоли головного мозга, рака головы и шеи; инфекционное заболевание выбрано из бактериальной инфекции и вирусной инфекции; аутоиммунное заболевание выбрано из органоспецифического аутоиммунного заболевания и системного аутоиммунного заболевания; где органоспецифическое аутоиммунное заболевание включает хронический лимфоцитарный тиреоидит, гипертиреоз, сахарный инсулинзависимый диабет, тяжелую миастению, язвенный колит, злокачественную анемию с хроническим атрофическим гастритом, легочный геморрагический синдром с нефритом, первичный билиарный цирроз, множественный рассеянный склероз и острый идиопатический полиневрит; системные аутоиммунные заболевания включают ревматоидный артрит, системную красную волчанку, системный васкулит, склеродермию, пемфигус, дерматомиозит, смешанное заболевание соединительной ткани и аутоиммунную гемолитическую анемию.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610343960 | 2016-05-23 | ||
CN201610343960.7 | 2016-05-23 | ||
PCT/CN2017/085417 WO2017202273A1 (zh) | 2016-05-23 | 2017-05-23 | 苄苯醚类衍生物、及其制法和药物组合物与用途 |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018145009A true RU2018145009A (ru) | 2020-06-25 |
RU2018145009A3 RU2018145009A3 (ru) | 2020-06-25 |
RU2743165C2 RU2743165C2 (ru) | 2021-02-15 |
Family
ID=60411053
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018145534A RU2744975C2 (ru) | 2016-05-23 | 2017-05-23 | Фенилатное производное, получение и фармацевтическая композиция и применение |
RU2018145296A RU2735541C2 (ru) | 2016-05-23 | 2017-05-23 | Простое эфирное производное никотинилового спирта, получение и фармацевтическая композиция и применения |
RU2018145009A RU2743165C2 (ru) | 2016-05-23 | 2017-05-23 | Производное бензилфенилового эфира, способ его получения и его фармацевтическая композиция и применение |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018145534A RU2744975C2 (ru) | 2016-05-23 | 2017-05-23 | Фенилатное производное, получение и фармацевтическая композиция и применение |
RU2018145296A RU2735541C2 (ru) | 2016-05-23 | 2017-05-23 | Простое эфирное производное никотинилового спирта, получение и фармацевтическая композиция и применения |
Country Status (7)
Country | Link |
---|---|
US (4) | US10815208B2 (ru) |
EP (4) | EP3459926B1 (ru) |
JP (3) | JP6905053B2 (ru) |
KR (3) | KR102364344B1 (ru) |
CN (10) | CN107417564A (ru) |
RU (3) | RU2744975C2 (ru) |
WO (5) | WO2017202273A1 (ru) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107417564A (zh) | 2016-05-23 | 2017-12-01 | 中国医学科学院药物研究所 | 苯醚类衍生物、及其制法和药物组合物与用途 |
CN109803651B (zh) | 2016-06-27 | 2022-05-31 | 凯莫森特里克斯股份有限公司 | 免疫调节剂化合物 |
CN108250159B (zh) * | 2016-12-29 | 2023-07-11 | 深圳微芯生物科技股份有限公司 | 脲类化合物、其制备方法及其应用 |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
KR102647257B1 (ko) | 2017-07-28 | 2024-03-13 | 케모센트릭스, 인크. | 면역조절제 화합물 |
US10392405B2 (en) | 2017-08-08 | 2019-08-27 | Chemocentryx, Inc. | Macrocyclic immunomodulators |
TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
WO2019165043A2 (en) | 2018-02-22 | 2019-08-29 | Chemocentryx, Inc. | Indane-amines as pd-l1 antagonists |
CA3093851A1 (en) * | 2018-03-29 | 2019-10-03 | Arbutus Biopharma Corporation | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
AU2019277632A1 (en) | 2018-05-31 | 2020-12-24 | National Cancer Center Japan | Biomarker for judging efficacy of immune checkpoint inhibitor |
US20210253614A1 (en) | 2018-05-31 | 2021-08-19 | Peloton Therapeutics, Inc. | Compositions and methods for inhibiting cd73 |
EP4234030A3 (en) | 2018-07-13 | 2023-10-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
CN109305934A (zh) * | 2018-08-07 | 2019-02-05 | 成都海博锐药业有限公司 | 苯醚类衍生物及可药用盐、医药上的用途 |
CN110872275A (zh) * | 2018-08-31 | 2020-03-10 | 深圳微芯生物科技股份有限公司 | 作为免疫调节剂的联苯化合物及其用途 |
TW202028212A (zh) | 2018-10-11 | 2020-08-01 | 日商小野藥品工業股份有限公司 | Sting促效化合物 |
CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
CN112876463B (zh) * | 2019-02-21 | 2022-11-11 | 厦门宝太生物科技股份有限公司 | 一种制备pd-l1拮抗剂的中间体及其制备方法 |
CN109761952A (zh) * | 2019-02-25 | 2019-05-17 | 南方医科大学 | 一种含取代联苯的间苯二酚甲醚衍生物及其用途 |
CN111662270A (zh) * | 2019-03-05 | 2020-09-15 | 中国医学科学院药物研究所 | 碘同位素标记苄苯醚衍生物、及其制法和药物组合物与用途 |
JP2022527892A (ja) | 2019-03-22 | 2022-06-07 | グアンジョウ マキシノベル ファーマシューティカルズ カンパニー リミテッド | 小分子pd-1/pd-l1阻害剤、pd-l1抗体との医薬組成物及びその使用 |
MX2021013819A (es) | 2019-05-15 | 2022-02-10 | Chemocentryx Inc | Compuestos de triarilo para el tratamiento de enfermedades asociadas a pd-l1. |
CN111978287A (zh) * | 2019-05-23 | 2020-11-24 | 中国科学院上海有机化学研究所 | 一类免疫检查点小分子抑制剂及其制备方法和用途 |
CN112028870B (zh) * | 2019-06-04 | 2021-11-05 | 中国科学院上海药物研究所 | 一种具有苄氧基芳环结构的化合物,其制备方法和用途 |
CA3139242A1 (en) | 2019-06-20 | 2020-12-24 | Viengkham Malathong | Compounds for treatment of pd-l1 diseases |
WO2021007386A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
MX2022001434A (es) | 2019-08-05 | 2022-02-22 | Ono Pharmaceutical Co | Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios. |
CN110256290A (zh) * | 2019-08-06 | 2019-09-20 | 宜春学院 | 一种4-氰基苄氧基-4′-氰基苯基醚的制备方法 |
KR20220061184A (ko) * | 2019-09-09 | 2022-05-12 | 인스티튜드 오브 머테리아 메디카, 차이니스 아케데미 오브 메디컬 싸이언시스 | 니코티닐 알코올 에테르 유도체의 말레에이트, 이의 결정형, 및 이의 응용 |
KR20220083775A (ko) | 2019-10-16 | 2022-06-20 | 케모센트릭스, 인크. | Pd-l1 질환의 치료를 위한 헤테로아릴-바이페닐 아민 |
AU2020368393A1 (en) | 2019-10-16 | 2022-04-21 | Chemocentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases |
CN111187172B (zh) * | 2020-01-20 | 2021-10-29 | 中国药科大学 | 硝基苯醚类化合物、其制备方法和药物组合物与用途 |
TW202200161A (zh) | 2020-03-20 | 2022-01-01 | 美商基利科學股份有限公司 | 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法 |
CN113444075A (zh) * | 2020-03-27 | 2021-09-28 | 中国医学科学院药物研究所 | 二氢吲哚衍生物、及其制法和药物组合物与用途 |
WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
EP4134134A4 (en) | 2020-04-10 | 2023-12-27 | ONO Pharmaceutical Co., Ltd. | STING AGONIST COMPOUND |
CN111333629B (zh) * | 2020-04-10 | 2021-03-05 | 颜建发 | 苯基-1h-吡唑类衍生物及其在抗肿瘤药物中的应用 |
CN113563260A (zh) * | 2020-04-28 | 2021-10-29 | 药康众拓(江苏)医药科技有限公司 | 苯甲酰胺类化合物、制备方法及用途 |
WO2021226206A2 (en) | 2020-05-05 | 2021-11-11 | Teon Therapeutics, Inc. | Cannabinoid receptor type 2 (cb2) modulators and uses thereof |
CN114075123B (zh) * | 2020-08-11 | 2023-06-06 | 中国人民解放军军事科学院军事医学研究院 | 苄胺类衍生物及其制备方法与用途 |
CN111943876B (zh) * | 2020-09-08 | 2022-04-19 | 江苏省原子医学研究所 | 一种n2s2类溴代苄醚衍生物、制备方法及应用 |
CN113135895A (zh) * | 2021-04-30 | 2021-07-20 | 中国药科大学 | 一种新型联苯类衍生物及其制备方法与医药用途 |
WO2023034530A1 (en) | 2021-09-02 | 2023-03-09 | Teon Therapeutics, Inc. | Methods of improving growth and function of immune cells |
WO2023050104A1 (zh) * | 2021-09-28 | 2023-04-06 | 中国医学科学院药物研究所 | 二氢吲哚衍生物、及其制法和药物组合物与用途 |
WO2023081730A1 (en) | 2021-11-03 | 2023-05-11 | Teon Therapeutics, Inc. | 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer |
WO2023097211A1 (en) | 2021-11-24 | 2023-06-01 | The University Of Southern California | Methods for enhancing immune checkpoint inhibitor therapy |
CN114181144B (zh) * | 2021-12-06 | 2023-04-04 | 浙江工业大学 | 一种氟代联苯甲基间苯二酚醚类衍生物、其制备方法和应用 |
WO2023104744A1 (en) * | 2021-12-06 | 2023-06-15 | Helmholtz-Zentrum Dresden-Rossendorf E.V. | 3-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereof |
CN114956977B (zh) * | 2022-06-09 | 2024-03-26 | 朗捷睿(苏州)生物科技有限公司 | 一种联苯类化合物、药物组合物及其制备方法和应用 |
WO2024015372A1 (en) | 2022-07-14 | 2024-01-18 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
CN115417870B (zh) * | 2022-09-20 | 2024-02-27 | 中国药科大学 | Pd-l1&nampt双靶点抑制剂和用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4329518A (en) | 1979-09-18 | 1982-05-11 | Fmc Corporation | Insecticidal [1,1'-biphenyl]-3-ylmethyl esters |
ZA816442B (en) * | 1980-10-02 | 1982-12-29 | Fmc Corp | Insecticidal(1,1'-biphenyl)-3-ylmethyl esters |
RU2144526C1 (ru) | 1994-08-04 | 2000-01-20 | Сумитомо Кемикал Компани, Лимитед | Дигалоидпропеновые соединения, инсектицидно-акарицидные средства, содержащие их, и промежуточные соединения для их получения |
US6291465B1 (en) | 1999-03-09 | 2001-09-18 | Hoffmann-La Roche Inc. | Biphenyl derivatives |
JP4594611B2 (ja) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
CN1735408A (zh) | 2002-11-08 | 2006-02-15 | 武田药品工业株式会社 | 受体机能调节剂 |
JP2007114968A (ja) * | 2005-10-19 | 2007-05-10 | Junji Mizuma | バッテリの充電システムおよび充電方法 |
EP2001844A2 (en) * | 2006-03-14 | 2008-12-17 | Amgen, Inc | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
BRPI0922135B1 (pt) * | 2008-12-05 | 2021-07-13 | Astellas Pharma Inc | Composto de 2h-cromeno ou um sal do mesmo, composição farmacêutica compreendendo dito composto e uso do mesmo para prevenir ou tratar uma doença induzida por infiltração de linfócito indesejável associada com s1p1 |
CN101735408B (zh) | 2010-01-18 | 2011-12-21 | 中国海洋石油总公司 | 一种高装饰性醇酸-有机硅丙烯酸复合水性树脂 |
WO2013126428A1 (en) * | 2012-02-21 | 2013-08-29 | Allergan, Inc. | Phenoxy derivatives as sphingosine 1-phosphate (s1p) receptor modulators |
CA2917614A1 (en) * | 2013-07-18 | 2015-01-22 | Novartis Ag | Aminomethyl-biaryl derivatives complement factor d inhibitors and uses thereof |
ES2642074T3 (es) * | 2013-09-04 | 2017-11-15 | Bristol-Myers Squibb Company | Compuestos útiles como inmunomoduladores |
CN103787902B (zh) * | 2014-02-17 | 2016-08-17 | 华东理工大学 | 苄基取代的苯胺类化合物及其应用 |
US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
CN107417564A (zh) * | 2016-05-23 | 2017-12-01 | 中国医学科学院药物研究所 | 苯醚类衍生物、及其制法和药物组合物与用途 |
-
2017
- 2017-05-23 CN CN201710359979.5A patent/CN107417564A/zh active Pending
- 2017-05-23 EP EP17802122.6A patent/EP3459926B1/en active Active
- 2017-05-23 CN CN201710363523.6A patent/CN107417506A/zh active Pending
- 2017-05-23 CN CN201780031943.2A patent/CN109195960B/zh active Active
- 2017-05-23 WO PCT/CN2017/085417 patent/WO2017202273A1/zh unknown
- 2017-05-23 US US16/303,650 patent/US10815208B2/en active Active
- 2017-05-23 KR KR1020187037378A patent/KR102364344B1/ko active IP Right Grant
- 2017-05-23 WO PCT/CN2017/085421 patent/WO2017202277A1/zh unknown
- 2017-05-23 WO PCT/CN2017/085420 patent/WO2017202276A1/zh unknown
- 2017-05-23 CN CN202210287082.7A patent/CN114853634A/zh active Pending
- 2017-05-23 CN CN201780031899.5A patent/CN109311792B/zh active Active
- 2017-05-23 RU RU2018145534A patent/RU2744975C2/ru active
- 2017-05-23 RU RU2018145296A patent/RU2735541C2/ru active
- 2017-05-23 CN CN201780031898.0A patent/CN109219592B/zh active Active
- 2017-05-23 EP EP17802123.4A patent/EP3459925B1/en active Active
- 2017-05-23 US US16/303,649 patent/US10975049B2/en active Active
- 2017-05-23 EP EP17802120.0A patent/EP3466944B1/en active Active
- 2017-05-23 RU RU2018145009A patent/RU2743165C2/ru active
- 2017-05-23 JP JP2019514166A patent/JP6905053B2/ja active Active
- 2017-05-23 WO PCT/CN2017/085419 patent/WO2017202275A1/zh active Application Filing
- 2017-05-23 JP JP2019514168A patent/JP7075928B2/ja active Active
- 2017-05-23 CN CN201780031942.8A patent/CN109153626B/zh active Active
- 2017-05-23 JP JP2019514167A patent/JP6980767B2/ja active Active
- 2017-05-23 CN CN201780031954.0A patent/CN109153670B/zh active Active
- 2017-05-23 CN CN201710365671.1A patent/CN107417572A/zh active Pending
- 2017-05-23 EP EP17802119.2A patent/EP3450423B1/en active Active
- 2017-05-23 US US16/303,641 patent/US10882833B2/en active Active
- 2017-05-23 WO PCT/CN2017/085418 patent/WO2017202274A1/zh unknown
- 2017-05-23 US US16/303,646 patent/US10941129B2/en active Active
- 2017-05-23 KR KR1020187037129A patent/KR102456572B1/ko active IP Right Grant
- 2017-05-23 CN CN201710365696.1A patent/CN107417666A/zh active Pending
- 2017-05-23 KR KR1020187037375A patent/KR102400592B1/ko active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2018145009A (ru) | Производное бензилфенилового эфира, способ его получения и его фармацевтическая композиция и применение | |
EA202092169A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2 | |
CY1121601T1 (el) | Ενωσεις διαμιδιου που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα 2 αδρενεργικου υποδοχεα | |
MX2021013472A (es) | Moduladores de thr-? y metodos de uso de estos. | |
ZA202006378B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
RU2008127312A (ru) | Мезилатное пролекарство леводопы, его композиции и применение | |
CN108290869B (zh) | 用于在流感病毒感染中使用的杂环吲哚 | |
MX2021012756A (es) | Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este. | |
JP2020114831A (ja) | ビグアニド化合物及びその使用 | |
JPS6148494B2 (ru) | ||
AU2018216954B2 (en) | Piperazine derivatives for influenza virus inhibition | |
EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
SG190243A1 (en) | Hydroxamic acid derivatives and their use in the treatment of bacterial infections | |
EA200400762A1 (ru) | Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции | |
MX2022005732A (es) | Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina. | |
JP2015511232A5 (ru) | ||
KR101913789B1 (ko) | 코로나 바이러스 감염으로 인한 질환 치료용 화합물 | |
JP2015536928A5 (ru) | ||
JP2018519244A5 (ru) | ||
JP2015504917A5 (ru) | ||
WO2018141854A1 (en) | Piperazine derivatives for influenza virus inhibition | |
JP2009040767A5 (ru) | ||
RU2014138619A (ru) | Новые соли тримебутина на основе сульфонатов | |
MX2022006104A (es) | Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma. | |
MX2022006990A (es) | Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico. |